Results 81 to 90 of about 9,182 (184)
Skin Detachment and Regrowth in Toxic Epidermal Necrolysis
Case Reports in Dermatology, 2010 Toxic epidermal necrolysis is a rare but clinically well-described dermatological pathology. However, clinical pictures of this disorder in text books do not reflect its dynamic evolution.
Laurence Feldmeyer +4 more
doaj +1 more source
INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol
BJU International, Volume 138, Issue 4, Page 607-619, October 2026.Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan +13 more
wiley +1 more source
Contact Dermatitis, Volume 95, Issue 4, Page 349-357, October 2026.ABSTRACT Drug hypersensitivity reactions (DHRs) are common in children and are diagnostically challenging, with cutaneous manifestations being the most common presentation. Patch testing (PT) is a well‐established tool for investigating delayed T‐cell‐mediated reactions and is widely used in patients with contact dermatitis.
Gabriele Simonetti +7 more
wiley +1 more source
Arthritis Care &Research, Volume 78, Issue 9, Page 1265-1269, September 2026.Objective The American College of Rheumatology recommends HLA‐B*58:01 allele testing before the initiation of allopurinol, specifically among Asian and African American/Black patients, due to their increased risk for severe hypersensitivity reactions. However, testing rates remain low at many health care facilities.
Abimbola Fadairo‐Azinge +6 more
wiley +1 more source
Toxic epidermal necrolysis: A review
Journal of the American Academy of Dermatology, 1991 This article reviews the many facets of toxic epidermal necrolysis. Emphasis is placed on the importance of early diagnosis, burn unit placement, supportive care, and avoidance of systemic steroids. Discussion also includes other therapeutic options and the pathophysiology of the disease.
From the College of Pharmacy, the Division of Dermatology and Cutaneous Surgery ( host institution ) +4 more
openaire +3 more sources
Cancer Medicine, Volume 15, Issue 9, September 2026.ABSTRACT Background T‐cell–engaging bispecific antibodies are increasingly utilised in haematological malignancies and are beginning to be adopted in solid‐tumour treatment protocols. Cytokine release syndrome and neurotoxicity are well recognised, but target‐specific dermatological adverse event reporting patterns remain poorly defined.
Saikat Mandal +2 more
wiley +1 more source
A Challenging Case of Acute Methotrexate Toxicity
Clinical Case Reports, Volume 14, Issue 9, September 2026.ABSTRACT Catastrophic methotrexate toxicity, characterized by life‐threatening pancytopenia and neutropenic enterocolitis, may occur even after a single low therapeutic dose, particularly in patients with renal impairment or dehydration. Early recognition and prompt multidisciplinary management are essential to improve outcomes.
Sahel Asgari +3 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 9, September 2026.ABSTRACT Stevens‐Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap is a rare, life‐threatening mucocutaneous reaction typically induced by medications. Reports from Central America remain scarce. We present two contrasting cases of SJS/TEN overlap from Nicaragua.
Marvin Alfaro +2 more
wiley +1 more source
Journal of Inherited Metabolic Disease, Volume 49, Issue 5, September 2026.Wetzel et al. outline how individual omics methods contribute to the diagnosis of patients with rare, and particularly mitochondrial diseases, with a focus on how spatial proteomics is joining this multi‐omics stack. ABSTRACT Proteomics by mass spectrometry has rapidly matured from a niche method into a standard tool.
Simon Wetzel +2 more
wiley +1 more source